Introduction {#Sec1}
============

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder defined by age-inappropriate levels of inattention, impulsivity and hyperactivity (American Psychiatric Association [@CR2]). Autism spectrum disorder (ASD) is defined by impairments in communication, social interaction and by restricted and repetitive behaviours (American Psychiatric Association [@CR2]). There is increasing evidence for comorbidity between disorders (Rommelse et al. [@CR57]; Simonoff et al. [@CR70]; van der Meer et al. [@CR75]) and shared executive function deficits (Corbett et al. [@CR14]; Geurts et al. [@CR24]), in particular in motor response inhibition (Alderson et al. [@CR1]; Corbett et al. [@CR14]; Lipsyzc and Schachar [@CR37]; Robinson et al. [@CR55]), albeit less consistently in ASD (Ozonoff and Strayer [@CR48]; Raymaekers et al. [@CR53]). Furthermore, this has been associated with impulsiveness in ADHD and motor stereotypies in ASD (Langen et al. [@CR36]). This overlap was highlighted by recent changes to the DSM-V that allows co-diagnosis of ADHD and ASD (<http://www.dsm5.org/>).

In ADHD, there is consistent evidence of underactivation compared to controls in inferior/orbitofrontal frontal cortex (IFC/OFC), supplementary motor area (SMA) and caudate/thalamus during inhibition tasks (Cubillo et al. [@CR16]; Rubia [@CR58]; Rubia et al. [@CR59]; Rubia et al. [@CR62]; Rubia et al. [@CR65]; Cortese et al. [@CR15]; Hart et al. [@CR29]). In children with ASD, however, no study has investigated the neurofunctional underpinnings of response inhibition. In adults with ASD, fMRI studies report inconsistent findings of increased activation in left IFC and decreased activation in right IFC and anterior cingulate cortex (ACC) during the go/no-go task (Kana et al. [@CR32]; Schmitz et al. [@CR68]). Therefore, a key question is whether the underlying neurobiology of shared cognitive phenotypes is shared or disorder-specific.

Serotonin (SE) is involved in impulsiveness and motor inhibition (Robbins et al. [@CR54]) and although selective serotonin reuptake inhibitors (SSRIs) such as citalopram had no effect on SSRT in healthy subjects (Chamberlain et al. [@CR10]), fMRI studies showed that SSRIs and acute tryptophan depletion (ATD), which enhance/reduce SE levels, enhance/decrease inhibitory IFC/OFC-striatal activation, respectively (Lamar et al. [@CR34]; Lamar et al. [@CR35]; Rubia et al. [@CR61]).

Furthermore, there is evidence that 5-HT is involved in the pathology of both ADHD and ASD. Thus, polymorphisms of serotonergic genes have been associated with both ADHD and ASD (Rommelse et al. [@CR56]; Sinzig and Lehmkuhl [@CR71]). Moreover, biochemical serotonergic abnormalities have been implicated in both ADHD (Oades [@CR46]) and ASD (Zafeiriou et al. [@CR79]). Despite evidence for SE abnormalities in both disorders, few studies have investigated the clinical efficacy of SSRIs in ADHD and ASD. The SSRI fluoxetine, for example, has been shown to improve inattentiveness and hyperactivity in comorbid children with ADHD (Barrickman et al. [@CR4]; Gammon and Brown [@CR23]; Quintana et al. [@CR52]) and to improve communication, social interaction and stereotyped behaviours in children with ASD (DeLong et al. [@CR19]; DeLong et al. [@CR20]; Hollander et al. [@CR30]), albeit citalopram was not effective (King et al. [@CR33]).

Given the evidence for abnormalities in SE (Oades [@CR46]; Zafeiriou et al. [@CR79]) and inhibition in both disorders (Alderson et al. [@CR1]; Corbett et al. [@CR14]; Geurts et al. [@CR24]; Robinson et al. [@CR55]; Rommelse et al. [@CR57]) and serotonergic mediation of inhibitory control (Anderson et al. [@CR3]; Lamar et al. [@CR34]; Lamar et al. [@CR35]; Robbins et al. [@CR54]; Rubia et al. [@CR61]), an important question that may elucidate the potential neurotransmitter underpinnings of these cognitive abnormalities is whether SE modulates the inhibitory network in *both* ADHD and ASD and whether this modulation differs between disorders.

The aim of this fMRI study was therefore to investigate (1) shared and disorder-specific brain dysfunctions in ADHD and ASD boys during a tracking stop task and (2) shared and disorder-specific neurofunctional effects of an acute dose of fluoxetine on these inhibitory (dys)functions in both disorders. It has been argued that inferior frontal activation during stop task performance may be confounded by the attentional oddball effect of the low frequency appearance of stop signals (Hampshire et al. [@CR27]; Pauls et al. [@CR49]). Given that in this study we were particularly interested in the effects of fluoxetine on inhibitory rather than on attention networks, in our fMRI analysis we contrasted successful stop trials with failed stop trials in order to control for the attentional oddball effect of the low frequency appearance of the stop trials.

We hypothesised that, under placebo, ADHD boys compared to controls would show decreased IFC and caudate activation (Cortese et al. [@CR15]; Cubillo et al. [@CR16]; Cubillo et al. [@CR17]; Hart et al. [@CR29]; Rubia [@CR58]; Rubia et al. [@CR62]; Rubia et al. [@CR65]), whereas ASD boys would show increased left frontal activation (Schmitz et al. [@CR68]). We further hypothesised that fluoxetine compared to placebo, given its beneficial effects on symptoms, would normalise the abnormal activations in each disorder, i.e. it would increase the reduced fronto-striatal activation in ADHD, but reduce the increased left frontal abnormalities in ASD.

Materials and methods {#Sec2}
=====================

Participants {#Sec3}
------------

Sixty-two right-handed boys (Edinburgh Handedness Inventory) (Oldfield [@CR47]) (25 controls, 18 with ADHD and 19 with ASD) aged 10--17, IQ \> 70 (Wechsler Abbreviated Scale of Intelligence-Revised (WASI-R) (Wechsler [@CR76]) participated in this study.

ADHD boys had a clinical diagnosis of non-comorbid ADHD, inattentive/hyperactive-impulsive combined subtype, as assessed by an experienced child psychiatrist using the standardised Maudsley diagnostic interview that assesses ADHD according to DSM-IV criteria (Goldberg and Murray [@CR25]). They scored above clinical threshold for ADHD symptoms on the Strengths and Difficulties Questionnaire (SDQ) (Goodman and Scott [@CR26]) and the Conners' Parent Rating Scale-Revised (CPRS-R) (Conners et al. [@CR13]). Four of the ADHD boys were medication-naïve, three had ceased taking methylphenidate for a year (1), or 3 months (2) and 11 received chronic stimulants, but had a 48-h medication washout prior to scanning. ADHD boys were excluded if they scored above 15 on the Social Communication Questionnaire (SCQ) (Rutter et al. [@CR67]).

ASD diagnosis was made using ICD-10 (World Health Organisation (WHO) [@CR78]) diagnostic criteria and confirmed by the Autism Diagnostic Interview-Revised (ADI--R) (Lord et al. [@CR40]) and the Autism Diagnostic Observation Schedule (ADOS) (Lord et al. [@CR39]). All ASD subjects were medication-naïve apart from one patient, who took melatonin (but underwent a 2-week medication washout). ASD exclusion criteria included a score above 7 on the hyperactivity/inattention subscale of the SDQ or a *t* score above 70 on the DSM-IV subscale of the CPRS-R.

Exclusion criteria for all were comorbidity with other psychiatric or neurological disorders and drug/alcohol dependency. Patients were recruited from local clinics and support groups.

Patients were scanned twice in a double-blind, randomised, placebo-controlled design, using a Latin square randomization design for counter-balanced effects. Due to the half-life of fluoxetine (1--3 days) and its metabolite norfluoxetine (5--16 days) (Wong et al. [@CR77]), each scan was 3--4 weeks apart. To ensure that fluoxetine had reached its peak plasma levels, after 5--8 h (Wong et al. [@CR77]), patients were scanned 5 h after administration. Liquid fluoxetine was titrated to age and weight (see supplement). Placebo was equivalent amounts of peppermint water with similar taste to fluoxetine.

Twenty-five healthy, handedness and age-matched boys were recruited by advertisement and scored below clinical thresholds on the SDQ, SCQ and CPRS.

Participants gave written informed consent/assent. The study was approved by the local Ethics Committee. Participants were paid £50 for each scan.

For recruitment, demographic and clinical details of participants, see Table [1](#Tab1){ref-type="table"}. Table 1Sample characteristics for healthy control boys and patients with ADHD and ASDVariablesControls (25) mean (SD)ADHD (18) mean (SD)ASD (19) mean (SD)Age (years)13.4 (2.4)14.3 (1.8)14.7 (2.0)IQ109 (13)95 (11)112 (15)SDQ hyperactive-impulsive/inattentive subscale1.8 (1.6)9.2 (0.9)4.5 (1.8)SDQ---emotional distress subscale0.5 (0.8)3.6 (3.0)4.2 (3.0)SDQ---conduct subscale0.3 (0.7)5.0 (2.4)2.1 (2.0)SDQ---peer relations subscale.6 (1.1)3.4 (2.5)6.1 (2.4)SDQ---prosocial behaviour subscale9.1 (1.3)6.7 (2.3)5.1 (2.3)SDQ---total scores3.3 (2.9)21.2 (4.9)16.8 (5.7)SCQ total1.6 (2.7)7.0 (3.4)23.5 (5.5)CPRS-R total *T* score44 (3)83 (7)57 (8)ADOS communication scores----2 (1)ADOS social interaction scores----7 (4)ADOS communication and social scores----9 (5)ADOS stereotyped behaviour scores----1 (1)ADI communication scores----14 (4)ADI social Interaction scores----17 (5)ADI stereotyped scores----6 (3)*SDQ* Strengths and Difficulties Questionnaire, *SCQ* Social Communication Questionnaire, *CPRS-R* Conners' Parent Rating Scale-Revised, *ADOS* Autism Diagnostic Observation Schedule, *ADI* Autism Diagnostic Interview

FMRI paradigm: stop task {#Sec4}
------------------------

Subjects practised the task once prior to each scan under supervision of the researcher who made sure the participants understood the task and performed accordingly (by inhibiting more or less 50 % of trials). The 8 min 49 s minute visual tracking stop task requires withholding of an already triggered motor response to a go stimulus when it is followed unpredictably by a stop signal (Cubillo et al. [@CR17]; Rubia et al. [@CR60]; Rubia et al. [@CR64]; Rubia et al. [@CR65]; Rubia et al. [@CR66]). Subjects have to respond as quickly as possible to left or right pointing "go" arrows (500 ms duration, 80 % of 294 trials) with a left or right (thumb) button press, followed by a gap of 1100 to 1500 ms (which makes up a mean trial length of 1.8 s; jittered between 1.6 and 2 s to optimise statistical efficiency). In 20 % of trials (60), pseudo-randomly interspersed, and at least 3 repetition times apart for adequate separation of the hemodynamic response, go signals are followed (about 250 ms later) by arrows pointing upwards (300 ms duration) (stop signals), and subjects have to inhibit their motor response. A tracking algorithm changes the time interval between go and stop-signal onsets according to each subject's inhibitory performance, which is recalculated after each stop signal based on the average percentage of inhibition over previous stop trials to provide 50 % successful and 50 % unsuccessful inhibition trials (Supplementary Figure [S1](#MOESM1){ref-type="media"}).

Given that the contrast of stop-go trials is confounded by the attentional oddball effect of the low frequency of stop trials (20 %) relative to go trials (80 %), which also activates IFC (Hampshire et al. [@CR27]; Pauls et al. [@CR50]), for the fMRI analysis, brain activation to the 50 % unsuccessful stop trials was subtracted from the 50 % successful stop trials, controlling for the attentional oddball effect of the infrequent stop signal appearance.

The dependent inhibition variable is the stop signal reaction time (SSRT), calculated by subtracting the mean stop signal delay (SSD: the average time between go and stop signal at which the subject managed to inhibit to 50 % of trials) from the mean reaction time (MRT) to go trials, i.e. MRT-SSD (Logan et al. [@CR38]). MRT, intrasubject standard deviation of MRT, and omission error percentage are variables of the executive process of the task.

Data analysis {#Sec5}
=============

Analysis of performance data {#Sec6}
----------------------------

MANOVAs compared performance variables between controls and the two patient groups under placebo and between controls and the two patient groups under fluoxetine. Multiple repeated-measures ANOVAs within the two patient groups with group (ADHD, ASD) as independent factor and drug condition (placebo/fluoxetine) as repeated measures were conducted to test for group by medication interaction effects on performance.

FMRI image acquisition {#Sec7}
----------------------

Gradient-echo echoplanar MR imaging (EPI) data were acquired on a General Electric Signa 3T Horizon HDx system at the Centre for Neuroimaging Sciences, Institute of Psychiatry, King's College London, UK. A semiautomated quality control procedure ensured consistent image quality. A quadrature birdcage headcoil was used for RF transmission and reception. In each of 28 non-contiguous planes parallel to the anterior-posterior commissure, 296 T2\*-weighted MR images depicting BOLD contrast covering the whole brain were acquired with TE = 30 ms, TR = 1.8 s, flip angle = 75°, in-plane voxel-size = 3 mm, slice thickness = 5.5 mm and slice-skip = 0.5 mm. A whole-brain high-resolution structural scan (inversion recovery gradient echo planar image) on which to superimpose the individual activation maps, was also acquired in the inter-commissural plane with TE = 30 ms, TR = 3 s, flip angle = 90°, 43 slices, slice thickness = 3.0 mm, slice skip = 0.3 mm and in-plane voxel-size = 1.875 mm.

All subjects performed three other fMRI tasks which are not reported here.

FMRI image analysis {#Sec8}
-------------------

The XBAM software package was used (<http://www.brainmap.co.uk/>) (Brammer et al. [@CR5]) which makes no normality assumptions (often violated in fMRI data), but instead uses median statistics to control outlier effects and permutation rather than normal theory-based inference (Thirion et al. [@CR74]).

Individual- and group-level analyses are described in further detail elsewhere (Brammer et al. [@CR5]; Cubillo et al. [@CR17]; Rubia et al. [@CR64]; Rubia et al. [@CR65]; Rubia et al. [@CR66]) and in the supplementary material. Briefly, the fMRI data were realigned to minimise motion-related artefacts and smoothed using a Gaussian filter (FWHM 8.82 mm) (Bullmore et al. [@CR7]). Further data analysis included slice timing correction and the residual effects of motion were regressed out from the time series (using the estimated motion parameters) before fitting a general linear model. Time-series analysis of individual subject activation was performed with a wavelet-based resampling method previously described (Bullmore et al. [@CR8]). We convolved the task epoch of the contrasts of interest (i.e. successful stop---implicit go trials; failed stop trials---implicit go trials) and the higher level contrast (successful stop-go trials minus unsuccessful stop-go trials) with two Poisson model functions (delays of 4 and 8 s). Individual activation maps were recalculated by testing the goodness-of-fit of this convolution with the BOLD time series; the goodness-of-fit calculation used the ratio of the sum of squares of deviations from the mean intensity value due to the model (fitted time series) divided by the sum of squares due to the residuals (original time series minus model time series). This statistic, the sum of squares (SSQ) ratio, was used in further analyses. Using rigid body and affine transformation, the individual maps were registered into Talairach standard space. A group brain activation map was then produced for each medication condition and each experimental condition (see supplementary material).

ANCOVA between-group difference analyses {#Sec9}
----------------------------------------

For between-group comparisons between controls and patients under either placebo or fluoxetine, one-way ANCOVA analyses with group as factor and rotational and translation movement in Euclidian 3-D space as covariate, were conducted using randomization-based tests for voxel or cluster-wise differences as described in detail elsewhere (Bullmore et al. [@CR8]; Bullmore et al. [@CR9]). For these between-group comparisons, less than one false activated cluster was expected at *p* \< 0.05 for voxel and *p* \< 0.01 for cluster comparisons. Given that right IFC was an a priori hypothesised region, we used a more lenient cluster level threshold of *p* \< 0.05 and also conducted a region of interest analysis using the IFC as a mask. Then the standardised BOLD response values for each participant were extracted for the significant clusters of the ANCOVA analyses and post hoc *t*-tests (correcting for multiple comparisons using least significant difference (LSD)) were conducted to identify the direction of the group differences.

ANCOVA within-patient interaction effects {#Sec10}
-----------------------------------------

A 2 × 2 ANCOVA (2 medication conditions, 2 groups) with rotational and translation movement as covariate was conducted using randomised-based testing for voxel or cluster-wise differences as described elsewhere (Bullmore et al. [@CR8]). Less than one false positive activation cluster was expected at *p* \< 0.05 at voxel and *p* \< 0.01 at cluster level. For our a priori hypothesised region in right IFC, a more lenient *p* \< 0.05 was used as well as a region of interest analysis using the IFC as a mask. Statistical measures of BOLD response for each participant were then extracted in each of the significant clusters and post hoc *t* tests (corrected for multiple comparisons with LSD) were conducted to identify the direction of the interaction effects.

Results {#Sec11}
=======

Participant characteristics {#Sec12}
---------------------------

ANOVAs showed no significant group differences in age (*F* (df = 2,61) = 3; n.s.) but in IQ (*F* (df = 2,61) = 10, *p* \< 0.001) which was significantly lower in ADHD relative to control and ASD boys (*p* \< 0.005), who did not differ. Given that ADHD children have typically lower IQ than their healthy peers (Bridgett and Walker [@CR6]), data were not covaried for IQ, as covarying for a measure that is associated with the condition would violate ANCOVA assumptions (Dennis et al. [@CR21]). Nonetheless, to assess the potential impact of IQ, analyses were repeated with IQ as covariate. For group differences in clinical measures, see Table [1](#Tab1){ref-type="table"}.

Performance data {#Sec13}
----------------

As expected, all subjects achieved approximately 50 % probability of inhibition, suggesting the algorithm was successful and there were no differences between controls and patient groups in this measure for either placebo (*F* (df = 2,61) = 1.2; *p* = n.s.) nor fluoxetine (*F* (df = 2,61) = 2.7, *p* = n.s.) nor were there any group or group by medication interaction effects for the within-patients analysis (F (df = 2,61) \< 1, *p* = n.s.). MANOVA showed a trend for a significant group effect for placebo (*F* (df = 8,114); *p* \< 0.08), which was due to increased omission errors between controls and patients under placebo (*F* (df = 2,61) = 4, *p* \< 0.02). Post hoc analyses (corrected for multiple testing using least significance difference (LDS)) showed that this was due to ADHD boys having increased omission errors than both control (*p* \< 0.05) and ASD boys (*p* \< 0.01) (Table [2](#Tab2){ref-type="table"}). MANOVA for fluoxetine showed no significant group effect (*F* (df = 2,61) = 1.2, *p* = n.s.).Table 2Performance measures for the stop task for healthy controls, ADHD and ASD groupsPerformance measureControlsADHD placeboADHD fluoxetineASD placeboASD fluoxetineMeanSDMeanSDMeanSDMeanSDMeanSDSSRT16110713281142109140125142103PI513503494503494SSD4622349727490304792748029MRT to go trials62310462986632109618102622113SD for MRT to go trials1743919444194601683916643Omission errors^a^5598993533*PI* percentage inhibition, *SSRT* stop signal reaction time, *SSD* average stop signal delay, *MRT* mean reaction timeSD = intrasubject variability of reaction time (in ms)^a^ADHD \> C, ASD

Within the patient groups there were no significant group (df = 1,35) or group by medication interaction effects (df = 1,35) for any variables (*F* \< 1 for all measures).

Given that ADHD patients performed the task twice, but controls only once, we also measured practice effects in the ADHD group using repeated measures *t* tests between performance measures at scans 1 and 2. No significant differences were found (*F* (df = 1,17) = 0.02, *p* = n.s.).

FMRI data {#Sec14}
---------

### Movement {#Sec15}

The Euclidean formula described below was used to produce a 3-D movement value known as *d* which is representative of movement in *x*, *y* and *z*. The formula was used to produce a *d* value for the maximum translation and maximum rotation of each participant.$$\documentclass[12pt]{minimal}
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Repeated measures ANOVAs showed no significant group by movement interaction effects in the Euclidean measures of maximum xyz rotation (*F* (df = 4118) = 2, *p* = 0.14) or maximum xyz translation (*F*(df = 4118) = 1, *p* = 0.58). Nevertheless, to eliminate any potential effects of non-significant variance in motion, these Euclidean motion parameters for maximum xyz translation and rotation were used as covariates in the fMRI analyses.

Within-group activations are reported in the supplementary results section and in supplementary Figs. [S2](#MOESM1){ref-type="media"} and [S3](#MOESM1){ref-type="media"}.

Between-group differences between controls and patients under placebo {#Sec16}
---------------------------------------------------------------------

ANCOVA between controls and patients on placebo showed significant group differences in left middle/IFC, left OFC/superior temporal lobe (STL) reaching into putamen and globus pallidus and in left inferior parietal lobe (IPL). The hypothesised difference in right IFC was observed at a more lenient *p* \< 0.05 (Fig. [1a](#Fig1){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}) and confirmed by a region of interest analysis (Talairach coordinates (x;y;z) = 54;7;26; BA 45; 10 voxels).Fig. 1Between-group brain activation differences between controls and patients under placebo or fluoxetine for the contrast of successful stop with unsuccessful stop trials. **a** Axial sections showing the between-group ANCOVA comparison findings between controls and patients under placebo. Shown underneath are the statistical measures of BOLD response for each of the three groups for each of the brain regions that showed a significant group effect. **b** Axial sections for the between-group ANCOVA comparison between controls and patients under fluoxetine. Talairach *z* coordinates are indicated for slice distance (in mm) from the intercommissural line. The right side of the image corresponds to the right side of the brainTable 3Brain activation differences between controls and patients on placebo or fluoxetinePost hoc group differencesBrain regions of activation differencesBrodmann area (BA)Peak Talairach coordinates (x;y;z)VoxelsCluster *p* valuePlacebo C \< ASDR inferior frontal cortex4454;15;26160.03 C, ADHD \< ASDL inferior/middle frontal cortex44/45/46/9−40;30;23820.002 C, ASD \> ADHDL STL/OFC/putamen/globus pallidus38/47/11/25−29;11;−26730.008 C \> ADHD \> ASDL inferior parietal lobe40−29;−22;40970.002Fluoxetine C, ASD \> ADHDL + R pre-SMA/premotor/superior frontal cortex6/8−11;4;632030.0006 C \< ADHD, ASDSMA proper6/8/9−4;−11;50420.007 ADHD \< C \< ASDR inferior parietal lobe/angular gyrus636;−63;30500.004 C, ASD \> ADHDL inferior parietal lobe/middle temporal40/39−47;−63;261880.0002 C \< ASD \< ADHDPrecuneus40/397;−67;431140.002*STL* superior temporal lobe, *OFC* Orbitofrontal cortex, *SMA* supplementary motor area

Post hoc analyses showed that the group effect in right IFC was due to significantly increased activation in ASD relative to control boys (*p* \< 0.005) and trend-wise compared to ADHD boys (*p* \< 0.08). In left middle/IFC, ASD patients had significantly increased activation compared to both control and ADHD boys (*p* \< 0.005) who activated this region during failed inhibition and had a trend-wise reduction relative to controls (*p* \< 0.08). In left OFC/STL/basal ganglia both control and ASD boys, who did not differ from each other, showed increased activation relative to ADHD boys who activated this area during failed inhibition (*p* \< 0.005). Left IPL was significantly reduced in both patient groups relative to controls (*p* \< 0.05), with ASD patients activating this area significantly more during failed inhibition than ADHD (*p* \< 0.05).

To test whether group effects were related to task performance, we correlated all clusters with SSRT and omission errors, since they were lower in ADHD relative to controls and ASD. The (reduced) activation in left OFC/basal ganglia in ADHD was significantly negatively correlated with omission errors (*r* = −0.5, *p* \< 0.05). No other correlations were significant.

Between-group differences between controls and patients under fluoxetine {#Sec17}
------------------------------------------------------------------------

There were significant group differences in bilateral pre-SMA/superior frontal cortex, SMA proper, left IPL/middle temporal lobe, right IPL and precuneus (Fig. [1b](#Fig1){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}). Post hoc analyses showed that control and ASD boys, who did not differ, activated pre-SMA/superior frontal cortex significantly more during successful inhibition than ADHD boys who activated this cluster more during failed inhibition (*p* \< 0.0001). SMA proper was significantly more activated in patients, who did not differ relative to controls, who activated this region more during failed inhibition (*p* \< 0.05). In bilateral IPL, controls and ASD boys had increased activation during successful inhibition relative to ADHD boys who activated this region more during failed inhibition (*p* \< 0.05). In right IPL, ASD boys also had increased activation relative to controls (*p* \< 0.05). In precuneus, ADHD boys showed significantly enhanced activation for successful inhibition relative to both ASD (*p* \< 0.05) and controls who activated this region during failed inhibition and differed relative to ASD (*p* \< 0.05). Correlations with behaviour showed that activation in pre-SMA/superior frontal cortex during successful inhibition was negatively correlated with SSRT in the ASD group (*r* = −0.532, *p* \< 0.05). Activation in precuneus was negatively correlated with SSRT in the ADHD group (*r* = −0.493, *p* \< 0.05).

Effect size comparisons of case-control conditions to test for significant "normalisation" effects {#Sec18}
--------------------------------------------------------------------------------------------------

To establish whether the group differences between controls and patients under each drug condition (ADHD/ASD under placebo versus controls; ADHD/ASD under fluoxetine versus controls) were significantly different, we directly compared the effect sizes (ES) of the group differences from the two case-control comparisons (Matthews and Altman [@CR42]).

When comparing two effect sizes, the *z* test can evaluate the likelihood of whether they are significantly heterogeneous. The difference between the two effect sizes can be considered a normalized variable, where the standard error of the difference is a combination of the standard errors of the two comparisons. Based upon this, the probability of a type I error can be calculated using the formula: *p* (*α*) = (es~1~ − es~2~)/sqrt(se~1~^2^ + se~2~^2^).

For the abnormalities in the ADHD patients, the effect sizes of the ADHD placebo-control contrast was not significantly different from the effect sizes of the ADHD fluoxetine-control comparison for left OFC (*z* = −0.9, *p* = n.s.), right IFC (*z* = −0.6; *p* = n.s.) or the left inferior parietal activation clusters (*z* = 0.53, *p* = n.s.), suggesting that the normalisation effects in these clusters were not statistically significant.

For the abnormalities in the ASD patients, however, the effect sizes for the ASD placebo-control contrast were significantly different from the effect sizes for the ASD fluoxetine-control contrast for left IFC (*z* = 2.8, *p* \< 0.005) and right IFC (*z* = −2.5, *p* \< 0.01), both of which were enhanced under placebo but normalised under fluoxetine, and for left inferior parietal lobe, which was significantly reduced in ASD relative to controls under placebo, but enhanced under fluoxetine (*z* = 2.3, *p* \< 0.02). The findings show that all normalisation effects in these clusters were statistically significant.

Control for IQ {#Sec19}
--------------

To assess the potential impact of IQ on case-control group differences, all analyses were repeated with IQ as a covariate. All clusters remained at a *p* \< 0.01, apart from left OFC in the placebo between-group ANCOVA and right IPL in the fluoxetine between-group ANCOVA, which survived at a more lenient *p* \< 0.05.

Within-patients group by medication interaction effects {#Sec20}
-------------------------------------------------------

ANCOVA analysis with group as dependent variable and drug as within-group variable showed a significant group by medication interaction effect in five clusters. (1) Fluoxetine reduced pre-SMA activation in ADHD boys, whereas it increased it in ASD boys during successful inhibition (*p* \< 0.005). (2) Fluoxetine increased activation in left OFC/STL/putamen/globus pallidus in ADHD during successful inhibition relative to placebo, but reduced it in ASD (*p* \< 0.05). (3) Both patient groups activated left IPL during failed inhibition under placebo, but ADHD boys activated this region more during failed inhibition and ASD boys more during successful inhibition under fluoxetine (*p* \< 0.0001). (4) Right cerebellum activation was increased under fluoxetine in ADHD relative to placebo for successful inhibition, while ASD boys activated this area during failed inhibition under both placebo and fluoxetine (*p* \< 0.05). (5) At a more lenient *p* \< 0.05, relative to placebo, fluoxetine increased activation in the hypothesised right IFC during successful inhibition in ADHD and decreased it in ASD (*p* \< 0.05) (Fig. [2](#Fig2){ref-type="fig"}, Table [4](#Tab4){ref-type="table"}). The same cluster was also confirmed by a region-of-interest analysis (Talairach coordinates (x;y;z) = 51;4;30; BA 45; 7 voxels).Fig. 2Within-patient group by medication interaction effects. Axial sections showing within-patient group by medication interaction effects for the contrast of successful stop-unsuccessful stop trials. Shown underneath are the statistical measures of BOLD response for each of the brain regions that showed a significant group by medication interaction effect within patients. Talairach *z* coordinates are indicated for slice distance (in mm) from the intercommissural line. The right side of the image corresponds to the right side of the brainTable 4Group by drug interaction effects within ADHD and ASD patientsBrain regions of activationBrodmann area (BA)Peak Talairach coordinates (x;y;z)VoxelsCluster *p* valueR inferior/middle frontal cortex44/951;0;26210.03R pre-SMA/premotor/superior frontal cortex6/8−7:33;5610850.0003L STL/OFC/putamen/globus pallidus38/47/11/25−4;−7;−264520.004L inferior parietal/middle/STL/occipital lobe39/40/22/19−43;−67;302370.008R cerebellum22;−41;−171390.0005*STL* superior temporal lobe, *OFC* orbitofrontal cortex, *SMA* supplementary motor area

No significant correlations with performance were observed. All findings remained when IQ was covaried for.

Discussion {#Sec21}
==========

The findings reveal opposite brain dysfunction patterns in inhibitory brain regions in ADHD and ASD as well as opposite disorder-dissociated modulation effects of fluoxetine on these neurofunctional abnormalities. Relative to controls, ADHD patients showed reduced left OFC/basal ganglia activation, whereas ASD patients showed enhanced bilateral ventrolateral prefrontal activation relative to ADHD and controls. Fluoxetine normalized these disorder-dissociated brain abnormalities relative to controls, via disorder-dissociated opposite effects within patients: fluoxetine enhanced the abnormally reduced OFC/basal ganglia activation in ADHD, but reduced it in ASD. In contrast, it reduced the abnormally enhanced IFC activation in ASD, but enhanced it in ADHD. However, rigorous testing for the significance of these normalisation effects showed that these were only significant for the abnormality clusters in ASD. Furthermore, fluoxetine also had opposite disorder-dissociated effects on other inhibition areas such as pre-SMA and cerebellum: these were, respectively, enhanced (SMA) and reduced (cerebellum) in ADHD with fluoxetine relative to placebo, but reduced (SMA) and enhanced (cerebellum) in ASD.

The finding of disorder-specific increased activation in ASD relative to controls and ADHD in the left and right (trend-wise significant relative to ADHD) IFC extends our previous finding of increased left IFC activation in young adults with Asperger\'s syndrome during a go/no-go task (Schmitz et al. [@CR68]) by demonstrating disorder-specificity relative to ADHD. Predominantly, the right (Chambers et al. [@CR11]; Rubia et al. [@CR64]) but also left IFC (Hampshire et al. [@CR27]; Rubia et al. [@CR60]; Rubia et al. [@CR63]; Rubia et al. [@CR66]) are crucial areas mediating response inhibition and ASD patients may have needed to recruit these areas more for comparable task performance. ADHD patients had no underactivation in these areas relative to controls, unlike observed previously (Cubillo et al. [@CR17]; Hart et al. [@CR29]; Rubia [@CR58]; Rubia et al. [@CR62]; Rubia et al. [@CR65]), but relative to ASD. This, and the lack of a significant difference between controls and ADHD boys in SSRT may be due to long-term effects of stimulant medication, which has been associated with more normal prefrontal and striatal function (Hart et al. [@CR28]; Hart et al. [@CR29]; Rubia et al. [@CR59]), as 11 of the ADHD boys were on chronic methylphenidate medication, even if taken off medication prior to the scan. It is also interesting to note that the enhanced omission errors which were observed in ADHD patients relative to both control and ASD boys under placebo were correlated with reduced IFC-striatal activation under placebo. It has been suggested that omission errors are indicative of an alternative strategy that ADHD boys may employ to decrease their number of failed inhibitions (Tannock et al. [@CR73]). Therefore, although there was no behavioural evidence for poor inhibitory performance using the inhibitory measure of the SSRT, there were significant behavioural differences in omission errors in ADHD patients under placebo. The differences correlated with the neurofunctional deficits and were no longer observed under fluoxetine. The disorder-exclusive deficits in ADHD adolescents in the left OFC/basal ganglia relative to controls extend prior findings of OFC-striatal deficits in ADHD (Cubillo et al. [@CR17]; Hart et al. [@CR29]; Rubia [@CR58]; Rubia et al. [@CR62]; Rubia et al. [@CR65]; Rubia et al. [@CR59]). Our results therefore show disorder-dissociated frontal lobe dysfunctions in ADHD and ASD boys during inhibition relative to controls: with ASD patients showing significantly enhanced bilateral IFC activation and ADHD boys showing significantly reduced OFC/basal ganglia activation, which furthermore correlated with their enhanced omission errors during task performance.

Fluoxetine normalized all disorder-dissociated frontal brain dysfunctions due to opposite modulation effects in both disorders, which were, however, only significant in the ASD group. Fluoxetine significantly reduced bilateral OFC activation in the ASD group but enhanced it in ADHD. Under fluoxetine, ADHD patients also no longer showed enhanced omission errors, which were reduced under placebo and correlated with the OFC deficits. Fluoxetine also had an opposite up/downregulation effect on another key inhibition region, the pre-SMA: this was upregulated in ASD and hence increased relative to controls and ADHD, but downregulated in ADHD and hence reduced relative to controls and ASD. The upregulation effect of fluoxetine on right IFC and left OFC-striatal regions in ADHD extends prior evidence on SE agonist modulation of these areas in healthy adults during inhibitory control (Del-Ben et al. [@CR18]) to the ADHD population. Most intriguing, however, are the consistently opposite reduction effects of fluoxetine on these frontal activations in the ASD group. Opposite activation effects could possibly reflect group differences in baseline SE levels, as evidenced by lower platelet SE levels in ADHD children compared to controls (Spivak et al. [@CR72]), and increased baseline platelet, blood and prefrontal SE levels in 30 % of individuals with ASD relative to controls (Hranilovic et al. [@CR31]; Mulder et al. [@CR43]; Nakamura et al. [@CR45]; Piven et al. [@CR51]). In addition, ASD patients have abnormal 5-HT synthesis (Chugani et al. [@CR12]), 5-HT transporter (Makkonen et al. [@CR41]; Nakamura et al. [@CR45]) and 5-HT~2A~ receptor binding (Murphy et al. [@CR44]). Therefore, fluoxetine may increase the low SE baseline of children with ADHD to normal levels, leading to normalized activation in fronto-striatal areas. Whereas in children with ASD, the increase in SE in an already hyperserotonemic system may activate a negative feedback mechanism via activation of 5-HT~1A~ autoreceptors (Sibley et al. [@CR69]), leading to a decrease in SE and in fronto-striatal activation.

Despite significant modulation effects on brain activation, fluoxetine had no effect on inhibitory performance. However, the enhanced omission errors that were observed in ADHD patients under placebo relative to controls were no longer significant under fluoxetine. Furthermore, it is well documented that brain function is more sensitive to pharmacological manipulations than inhibitory performance (Cubillo et al. [@CR17]; Rubia et al. [@CR60]; Rubia et al. [@CR61]). In addition, one of the upregulated regions in ASD in a key inhibitory area, the pre-SMA, was correlated with SSRT, suggesting a relationship between activation changes and inhibitory performance.

The strengths of this study are carefully selected and non-comorbid patient groups who had no psychiatric comorbidities and, in the case of the ASD group, were medication-naïve. A limitation of this study is that for ethical and financial reasons, the control group was scanned only once, while patients were scanned twice which could have accounted for the lack of performance differences. The significantly lower IQ in the ADHD compared to the other two groups is another limitation. However, covariance analysis showed that the findings were not affected by IQ. Furthermore, stop task performance has been shown to be independent of IQ (Friedman et al. [@CR22]). Lastly, while the contrast of successful and unsuccessful stop trials controls for the attentional oddball effect of the low frequency of stop stimuli, it may be over-conservative, as during unsuccessful stop trials subjects may also attempt, but not achieve to inhibit.

Conclusions {#Sec22}
===========

To summarise, ADHD and ASD patients showed opposite brain activation abnormalities relative to controls: ADHD boys showed reduced while ASD boys enhanced frontal activation. Importantly, fluoxetine had a disorder-dissociated opposite effect on frontal brain dysfunctions, enhancing frontal activation in ADHD and reducing it in ASD which could suggest differential underlying SE baseline levels in the two disorders.
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